INIT.ST

Initiator Pharma A/S [INIT.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INIT.ST Stock Summary

Top 10 Correlated ETFs

INIT.ST

Top 10 Correlated Stocks

INIT.ST

In the News

INIT.ST Financial details

Company Rating
-
Market Cap
460.39M
Income
-27.26M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-11.46
Forward P/E
-
PEG
15.82
P/S
-
P/B
32.09
P/C
-
P/FCF
-11.33
Quick Ratio
10.68
Current Ratio
13.37
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.49
EPS next Y
-
EPS next Q
-
EPS this Y
35.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-55%
-
-
-
-
SMA20
-1.69%
SMA50
-9.99%
SMA100
-7.25%
Inst Own
-
Inst Trans
-
ROA
-100%
ROE
-132%
ROC
-1.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.0-12.2
52W High
-48%
52W Low
+24.8%
RSI
47.47
Rel Volume
0.47
Avg Volume
36.8K
Volume
17.16K
Perf Week
-1.58%
Perf Month
-10.22%
Perf Quarter
-13.33%
Perf Half Y
-13.33%
-
-
-
-
Beta
0.727
-
-
Volatility
0.15%, 0.31%
Prev Close
-0.32%
Price
6.24
Change
1.96%

Something similar

Top by Market Cap
META
BRH.DE
AMZN
TL0.DE
MSF.DE
Top Correlated ETFs
XMXD.L
SPOL.L
FTGG.DE
E903.DE
CES1.L
Top Correlated Stocks
DECB.BR
HDD.DE
ADN1.DE
UTDI.DE
1773.HK
Similar Market Cap
0218.HK
ASAAF
SLVRU
LECN.SW
LBIRD.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 36.8K
  • Market Capitalization 460.39M
  • Employee 3
  • CEO Dr. Claus Elsborg Olesen
  • Headquarters Copenhagen,DK
  • IPO Date 2017-03-16
  • Website https://www.initiatorpharma.com

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.